$DCTH News
Last published 10h ago
- 10h agoDCTHDelcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer TreatmentBusiness WireQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the Company will be featured on Health Uncensored with Dr. Drew in a segment titled “Precision Oncology: Changing the Game for Metastatic Liver Cancer.” The segment is scheduled to air nationally on Sunday ...
- 2d agoDCTHDelcath Systems Third Quarter 2026 Earnings Call - DELCATH SYSTEMS INCEarnings Call TranscriptsGood morning, ladies and gentlemen. Welcome to the DELCA Systems 3rd Quarter 2026 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answ
- 2d agoDCTHDelcath Systems Third Quarter 2026 Earnings Call - DELCATH SYSTEMS INCEarnings Call TranscriptsGood morning, ladies and gentlemen. Welcome to the DELCA Systems 3rd Quarter 2026 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answ
- 2d agoDCTHDelcath Systems Third Quarter 2026 Earnings Call - DELCATH SYSTEMS INCEarnings Call TranscriptsGood morning, ladies and gentlemen. Welcome to the DELCA Systems 3rd Quarter 2026 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answ
- 2d agoDCTHDELCATH SYSTEMS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoDCTHDelcath Systems Reports Third Quarter 2026 Results and Business HighlightsBusiness WireQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Total revenue of $35.1 million, compared with $20.6 million in the third quarter of ...
- 2w agoDCTHDelcath Systems to Participate in Upcoming Investor ConferencesBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor
- 2w agoDCTHDelcath Systems to Host Third Quarter 2026 Earnings CallBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 9, 2026, at
- 3w agoDCTHDelcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal MelanomaBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development
- 2mo agoDCTHDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireDelcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company
- 2mo agoDCTHDelcath Systems to Participate in Upcoming Investor ConferencesBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor
- 3mo agoDCTHApproval of Hepzato, Nda #201848 (REMS)FDA Approved DrugsApproval Date: 08/12/2026; Drug Name: Hepzato, Nda #201848; Active Ingredients: MELPHALAN HYDROCHLORIDE; Company: Delcath Systems Inc; Submission Status: Approval; Submission Classification: REMS; Application Number: 201848
- 3mo agoDCTHDelcath Systems Second Quarter 2026 Earnings Call - DELCATH SYSTEMS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the DELCAT Systems Second Quarter 2026 Earnings Conference Call. At this time, online is in listen-only mode. Following the presentation, we will conduct a question-and-
- 3mo agoDCTHDelcath Systems Second Quarter 2026 Earnings Call - DELCATH SYSTEMS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the DELCAT Systems Second Quarter 2026 Earnings Conference Call. At this time, online is in listen-only mode. Following the presentation, we will conduct a question-and-
- 3mo agoDCTHDelcath Systems Reports Second Quarter 2026 Results and Business HighlightsBusiness WireIncreases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary
- 3mo agoDCTHDelcath Systems to Participate at the Canaccord Genuity 46th Annual Growth ConferenceBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity
- 3mo agoDCTHDelcath Systems to Host Second Quarter 2026 Earnings CallBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30
- 3mo agoDCTHDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireDelcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company
- 4mo agoDCTHDelcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast CancerBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the European Institute
- 5mo agoDCTHDelcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress AbstractsBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated
- 6mo agoDCTHDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireDelcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity
- 6mo agoDCTHDelcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th
- 6mo agoDCTHDelcath Systems First Quarter 2026 Earnings CallDELCATH SYSTEMS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the DELCA Systems First Quarter 2026 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-an
- 6mo agoDCTHDelcath Systems Reports First Quarter 2026 Results and Business HighlightsBusiness Wire2026 Revenue Guidance of at least $100M Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic
- 6mo agoDCTHDelcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026Business WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective analysis by independent
- 6mo agoDCTHDelcath Systems to Host First Quarter 2026 Earnings CallBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM
- 7mo agoDCTHDelcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal MelanomaBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous
- 7mo agoDCTHDelcath Systems to Participate at the Society of Interventional Radiology 2026 MeetingBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will attend the Society of Interventional Radiology (SIR) 2026 Annual
- 8mo agoDCTHDelcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet OncologyBusiness WirePublication Highlights Promise of Combined Percutaneous Hepatic Perfusion and Immunotherapy in Metastatic Uveal Melanoma Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology
- 8mo agoDCTHDelcath Systems Fourth Quarter 2025 Earnings CallDELCATH SYSTEMS INCEarnings Call TranscriptsGreetings, and welcome to DelCast Systems' fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation.
- 8mo agoDCTHDelcath Systems Reports Fourth Quarter and Full Year 2025 ResultsBusiness WireConference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the
- 9mo agoDCTHDelcath Systems to Host Fourth Quarter and Full Year 2025 Earnings CallBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at
- 10mo agoDCTHDelcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results
- 10mo agoDCTHDelcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal MelanomaBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from
- 11mo agoDCTHDelcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal MelanomaBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective
- 11mo agoDCTHDelcath Systems Board of Directors Authorizes $25 Million Share Repurchase ProgramBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), ("Delcath") an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a
- 11mo agoDCTHDelcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal MelanomaBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a narrative
- 12mo agoDCTHDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireDelcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity
- 12mo agoDCTHDelcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma PatientsBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a
- 1y agoDCTHDelcath Systems to Participate in Upcoming Investor ConferencesBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor
- 1y agoDCTHDelcath Systems Reports Third Quarter 2025 Results and Business HighlightsBusiness WireConference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers,
- 1y agoDCTHDelcath Systems to Host Third Quarter 2025 Earnings CallBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 4, 2025, at
- 1y agoDCTHDelcath Systems Announces Preliminary Third Quarter 2025 Financial ResultsBusiness WireConference Call October 20, 8:45am EST Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and
- 1y agoDCTHDelcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary EndpointBusiness WireConference Call October 20, 8:45am EST Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the
- 1y agoDCTHDelcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 CongressBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on results from the
- 1y agoDCTHDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireDelcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity
- 1y agoDCTHDelcath Systems to Participate in Upcoming Investor ConferencesBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor
- 1y agoDCTHDelcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal CancerBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the City of Hope
- 1y agoDCTHDelcath Systems, Inc. (DCTH) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoDCTHDelcath Systems Reports Second Quarter 2025 Results and Business HighlightsBusiness WireConference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers,